Inspire Medical Systems Inc
For the period ended Sep 30, 2024. Filed Nov 4, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 4, 2024
INSP$64.33+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
Consolidated Statements of Cash Flows (unaudited)
(in thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net income (loss) | $18,285 | $(35,916) |
| Adjustments to reconcile net income (loss): | ||
| Depreciation and amortization | 4,072 | 2,029 |
| Accretion of investment discount | (7,317) | (69) |
| Stock-based compensation expense | 86,867 | 59,621 |
| Provision (benefit) for estimated credit losses | (1,133) | 1,340 |
| Other non-cash expenses | 1,106 | 1,258 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 1,347 | (11,588) |
| Inventories | (33,547) | (14,228) |
| Prepaid expenses and other current assets | (4,467) | (2,947) |
| Accounts payable | (3,357) | 11,075 |
| Accrued expenses and other liabilities | (791) | (3,189) |
| Net cash provided by operating activities | 61,065 | 7,386 |
| Investing activities | ||
| Purchases of property and equipment | (32,096) | (15,596) |
| Purchases of investments | (337,540) | (137,253) |
| Proceeds from sales or maturities of investments | 252,753 | 10,000 |
| Purchases of strategic investments | — | (250) |
| Net cash used in investing activities | (116,883) | (143,099) |
| Financing activities | ||
| Proceeds from the exercise of stock options | 23,359 | 24,506 |
| Payment of taxes on net share settlement of equity awards | (9,045) | (3,233) |
| Proceeds from issuance of common stock from employee stock purchase plan | 3,431 | 2,792 |
| Net cash provided by financing activities | 17,745 | 24,065 |
| Effect of exchange rate on cash | 48 | (47) |
| Decrease in cash and cash equivalents | (38,025) | (111,695) |
| Cash and cash equivalents at beginning of period | 185,537 | 441,592 |
| Cash and cash equivalents at end of period | $147,512 | $329,897 |
| Supplemental cash flow information | ||
| Property and equipment included in accounts payable and accrued expenses | $3,456 | $3,499 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.